By Kelly Cloonan
Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with schizophrenia.
The company said Tuesday a Phase 3 trial of Cobenfy as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale total score compared to a placebo with an atypical antipsychotic at week six.
The results missed the threshold for statistical significance for the primary endpoint, the company said.
Preliminary analyses suggest the treatment was associated with improved schizophrenia symptoms compared to the placebo treatment for certain patients.
A post-hoc subgroup analysis showed there was a notable difference in response between subjects treated with risperidone as a background therapy and those treated with other background antipsychotics.
The company said it plans to speak with regulators about potential next steps.
Shares fell 5.6% to $47.03 on Tuesday in after-hours trading. Shares have risen 1% over the last 12 months through Tuesday's close.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 22, 2025 17:00 ET (21:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。